Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00108719 |
RATIONALE: BMS-354825 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well BMS-354825 works in treating patients with blastic phase chronic myelogenous leukemia that did not respond to previous imatinib mesylate.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Drug: dasatinib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate |
Study Start Date: | January 2005 |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is an open-label, multicenter study.
Patients receive oral BMS-354825 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, on day 15 of course 1, on days 1 and 15 of courses 2 and 3, once a month in all subsequent courses, and at the completion of study treatment.
After completion of study treatment, patients are followed for at least 30 days.
PROJECTED ACCRUAL: A minimum of 60 patients will be accrued for this study within 6 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of blastic phase chronic myelogenous leukemia (CML), defined by ≥ 1 of the following criteria:
Previously treated with imatinib mesylate AND meets 1 of the following criteria:
Primary* or acquired** hematologic resistance to imatinib mesylate, defined as 1 of the following:
NOTE: **Disease responded to treatment with imatinib mesylate but subsequently progressed to accelerated phase CML
Intolerant to imatinib mesylate, defined as toxicity possibly related to treatment with imatinib mesylate at a dose ≤ 400 mg/day that led to discontinuation of therapy OR patient can only tolerate imatinib mesylate at doses < 400 mg/day
Patients who tolerate a dose of imatinib mesylate at 400 mg/day but are intolerant to higher doses are not considered intolerant to imatinib mesylate NOTE: Imatinib mesylate need not be the most recent treatment for CML prior to study entry
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
No history of significant bleeding disorder unrelated to CML, including any of the following:
Hepatic
Renal
Cardiovascular
Gastrointestinal
Other
Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
At least 5 days or 5 half-lives (whichever is greater) since prior and no concurrent drugs that carry a risk of causing torsades de pointes, including any of the following:
At least 5 days or 5 half-lives (whichever is greater) since prior and no concurrent medication that directly inhibits platelet function (except anagrelide for thrombocytosis due to CML), including any of the following:
At least 5 days or 5 half-lives (whichever is greater) since prior and no concurrent anticoagulant (e.g., warfarin, heparin, or low molecular weight heparin [e.g., danaparoid, dalteparin, tinzaparin, or enoxaparin])
United States, California | |
Jonsson Comprehensive Cancer Center at UCLA | |
Los Angeles, California, United States, 90095-1781 |
Study Chair: | Neil P. Shah, MD | Jonsson Comprehensive Cancer Center |
Study ID Numbers: | CDR0000422431, UCLA-0411069-01, BMS-CA180006, EUDRACT-2004-002516-28 |
Study First Received: | April 18, 2005 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00108719 |
Health Authority: | United States: Federal Government |
blastic phase chronic myelogenous leukemia Philadelphia chromosome positive chronic myelogenous leukemia relapsing chronic myelogenous leukemia |
Imatinib Philadelphia Chromosome Blast Crisis Leukemia Chronic myelogenous leukemia Hematologic Diseases |
Dasatinib Myeloproliferative Disorders Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Bone Marrow Diseases |
Neoplastic Processes Neoplasms Pathologic Processes Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions Cell Transformation, Neoplastic |